Tag: Biotechnology

Impact Newswire brings you the latest in Biotechnology news.

AZENTA
United States

AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ — Azenta, Inc. (Nasdaq: AZTA) (“Azenta” or “the Company”), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades … Continue reading AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

Impact Newswire
Infinimmune
United States

Infinimmune Appoints Dr. Tim Sullivan as Chief Business Officer

SAN FRANCISCO – Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced today the appointment of Tim Sullivan, Ph.D., as Chief Business Officer. In this newly created role, Dr. Sullivan, who has decades of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development initiatives, as well as corporate and product … Continue reading Infinimmune Appoints Dr. Tim Sullivan as Chief Business Officer

Impact Newswire
PureTech
United States

PureTech Appoints Michele Holcomb, PhD, to Board of Directors

Strategic healthcare leader brings more than 30 years of global experience to PureTech’s Board following notable positions with Cardinal Health, Teva Pharmaceuticals and McKinsey & Company BOSTON –PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Michele Holcomb, PhD, will join its board of directors as an … Continue reading PureTech Appoints Michele Holcomb, PhD, to Board of Directors

Impact Newswire
ENKO CHEM
United States

Enko Welcomes Tim Hassinger as the Company’s Newest Board Member

MYSTIC, Conn. – Tim Hassinger, CEO, President, and Chairman of the board of directors, Intelinair (Indianapolis), has joined Enko Chem, Inc., as the agricultural discovery company’s newest board member. Hassinger brings nearly forty years of experience in the agricultural industry. Prior to being named CEO and President of Intelinair in January 2022, he was CEO of Dow AgroSciences, the Indianapolis-based agricultural subsidiary of The Dow … Continue reading Enko Welcomes Tim Hassinger as the Company’s Newest Board Member

Impact Newswire
Mogrify
Untied Kingdom

Mogrify Appoints Dr Jonathan Appleby as Chief Scientific Officer

Strategic hire bolsters executive leadership team as Company progresses multiple therapeutic programs toward and into clinical development. CAMBRIDGE, England – Mogrify Limited (Mogrify®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need, announces the appointment of Dr Jonathan Appleby as Chief Scientific Officer. With decades of industry experience in translating both conventional and advanced therapeutic medicines, … Continue reading Mogrify Appoints Dr Jonathan Appleby as Chief Scientific Officer

Impact Newswire
Ophirex
United States

Ophirex Appoints Jeremy Gowler as Chief Executive Officer

Gowler Brings More than 20 Years of Biopharmaceutical Industry Leadership to Ophirex, Strengthening its Late-Stage Development and Growth Strategy CORTE MADERA, Calif. – Ophirex, Inc., a registered Public Benefit Corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, today announced the appointment of Jeremy Gowler as chief executive officer. Mr. Gowler also joins the Ophirex Board of Directors. … Continue reading Ophirex Appoints Jeremy Gowler as Chief Executive Officer

Impact Newswire
AffyImmune
United States

AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer

NATICK, Mass. – AffyImmune, a clinical-stage biotechnology company committed to developing novel, first-in-class CAR T cell therapies, today announced the appointment of Daniel Janse, Ph.D. as President and Chief Executive Officer. Dr. Janse brings twenty years of expertise and an extensive background in biopharmaceutical research and development, operations, and leadership to drive the company forward. “We are thrilled to welcome Dr. Janse as the new … Continue reading AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer

Impact Newswire
United States

BPGbio Appoints Esteemed Cancer Researcher Dr. Dipanjan Chowdhury to Scientific Advisory Board

Appointment Enhances Leadership in Protein Homeostasis and Oncology Translational Medicine BOSTON – BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced the addition of Dr. Dipanjan Chowdhury, a distinguished cancer researcher, to its Advisory Board. With his extensive expertise in early translational research and a deep understanding of aggressive solid tumors, Dr. Chowdhury will provide valuable guidance to enhance … Continue reading BPGbio Appoints Esteemed Cancer Researcher Dr. Dipanjan Chowdhury to Scientific Advisory Board

Impact Newswire
BioLoomics
United States

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

Former CSO of Trilo Therapeutics and Research Fellow at AbbVie joins to lead BioLoomics’ pipeline and combine lysosome targeting antibodies with ADCs BOULDER, Colo. – BioLoomics, a biotechnology company that targets peptide-antibody chimeras to specific compartments inside of diseased cells, announced today that Kurt Gish, Ph.D., has joined as the Chief Scientific Officer. Dr Gish will focus on building the company’s pipeline of lysosomal targeting … Continue reading BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

Impact Newswire